301207-46-5

Usage

InChI:InChI=1/C14H14N2O2/c1-18-13-8-3-2-7-12(13)14(17)16-11-6-4-5-10(15)9-11/h2-9H,15H2,1H3,(H,16,17)

Upstream product

• 68621-88-5 (3-aminophenyl)carbamic acid tert-butyl ester 

Downstream Products

• 1202038-22-9 C₂₁H₁₆Cl₂N₂O₃ 
• 1202038-24-1 C₂₁H₁₇FN₂O₃ 
• 331866-35-4 C₂₁H₁₇ClN₂O₃ 
• 625412-11-5 C₂₁H₁₇ClN₂O₃ 
• 1202038-25-2 C₂₂H₁₇F₃N₂O₃ 
• 1622869-25-3 C₂₃H₂₂N₂O₄ 
• 548454-47-3 C₂₂H₂₀N₂O₄ 
• 414906-18-6 C₂₁H₁₈N₂O₃ 
• 414900-55-3 C₂₂H₂₀N₂O₃ 
• 1192927-82-4 3,4,5-trimethoxy-N-(((3-(2-methoxybenzoyl)aminophenyl)amino)carbonothioyl)benzamide 
• 25228-82-4 2-Methoxy-N-(3-propionylamino-phenyl)-benzamide 

Relevant academic research and scientific papers

Discovery of arylamide-5-anilinoquinazoline-8-nitro derivatives as VEGFR-2 kinase inhibitors: Synthesis, in vitro biological evaluation and molecular docking

Herein, we embarked on a structural optimization campaign aiming at the discovery of novel anticancer agents with our previously reported XL-6f as a lead compound. A library of 23 compounds has been synthesized based on the highly conserved active site of VEGFR-2. Several title compounds exhibited selective inhibitory activities against VEGFR-2, which also displayed selective anti-proliferation potency against HepG2 cell. All synthesized compounds were evaluated for anti-angiogenesis capability. Compound 7o showed the most potent anti-angiogenesis ability, the efficient cytotoxic activities (in vitro against HUVEC and HepG2 cell lines with IC50 values of 0.58 and 0.23 μM, respectively). The molecular docking analysis revealed 7o is a Type-II inhibitor of VEGFR-2 kinase. In general, these results indicated these arylamide-5-anilinoquinazoline-8-nitro derivatives are promising inhibitors of VEGFR-2 for the potential treatment of anti-angiogenesis.

N-Acylthiourea and N-Acylurea Inhibitors of the Hedgehog Protein Signalling Pathway

The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or a

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.